Clinical Trial

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients with relapsed or refractory classic Hodgkin lymphoma (cHL) with response-adapted consolidation. This study will investigate using circulating tumor DNA (ctDNA) at pre-determined time points using Foresight CLARITY LDT, an ultra-sensitive liquid biopsy platform that detects Minimal residual disease (MRD) in patients with B-cell lymphomas using the phased variant enrichment and sequencing technology (PhasEDq) to determine response to study interventions.
Protocol Amendment History 4 changes
notable Primary completion pushed: 2029-05-31 -> 2029-07-31 2026-08-13
minor Completion pushed: 2033-12-31 -> 2034-03-31 2026-08-13
notable Primary completion pushed: 2029-03-31 -> 2029-05-31 2026-06-05
minor Completion pushed: 2033-10-31 -> 2033-12-31 2026-06-05
Trial Details
NCT Number NCT07021989
Lead Sponsor Michael Spinner, MD
Collaborators: UC Hematologic Malignancies Consortium (UCHMC), Foresight Diagnostics, Inc., Natera, Inc., Gateway for Cancer Research
Conditions Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Enrollment 38 participants
Start Date 2026-10-01
Primary Completion 2029-07-31 (estimated)
Study Completion 2034-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-12